Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Effekte bei Zielorganschädigung (16 Abbildungen)
Übersicht


Zum ersten Bild Abb. 9: Telmisartan - Renoprotektiver Effekt Abb. 10: Telmisartan - LVH Abb. 11: Telmisartan - LVH Abb. 12: Telmisartan - LVH Aktuelles Bild - Abb. 13: Telmisartan - LVH Abb. 14: Telmisartan - Arterienelastizität Abb. 15: Telmisartan - Arterienelastizität Abb. 16: Effekte bei Zielorganschädigung
Abbildung 13: Telmisartan - LVH
This clinical study assessed the effect of 12 months’ treatment with telmisartan 40–80 mg on LVMI in 90 patients with hypertension and echocardiographic evidence of mild-to-moderate LVH.1 There was a significant improvement in diastolic filling: the early to atrial filling ratio increased from 0.59 ± 0.2 at baseline to 0.88 ± 0.2 at study end (P<0.05). 1. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004; 97: 383–388.
 
Telmisartan - LVH
Vorheriges Bild Nächstes Bild   


Abbildung 13: Telmisartan - LVH
This clinical study assessed the effect of 12 months’ treatment with telmisartan 40–80 mg on LVMI in 90 patients with hypertension and echocardiographic evidence of mild-to-moderate LVH.1 There was a significant improvement in diastolic filling: the early to atrial filling ratio increased from 0.59 ± 0.2 at baseline to 0.88 ± 0.2 at study end (P<0.05). 1. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004; 97: 383–388.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung